Vanda Pharmaceuticals GAAP EPS of $0.06, revenue of $65.32M

• Vanda Pharmaceuticals press release (NASDAQ:VNDA): Q3 GAAP EPS of $0.06.
• Revenue of $65.32M (-6.8% Y/Y).
• Cash, cash equivalents and marketable securities (Cash) was $454.8 million as of September 30, 2022, representing an increase to Cash of $13.9 million, or 3%, compared to June 30, 2022.
• Revised 2022 Guidance: Revenue expected between $240 to $270 million, vs. prior guidance range of $240 to $280 million